IKT vs. PHXM, ENVB, WINT, EIGR, EVAX, LIAN, BRTX, BFRI, ATHE, and ERNA
Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include PHAXIAM Therapeutics (PHXM), Enveric Biosciences (ENVB), Windtree Therapeutics (WINT), Eiger BioPharmaceuticals (EIGR), Evaxion Biotech A/S (EVAX), LianBio (LIAN), BioRestorative Therapies (BRTX), Biofrontera (BFRI), Alterity Therapeutics (ATHE), and Eterna Therapeutics (ERNA). These companies are all part of the "medical" sector.
Inhibikase Therapeutics (NYSE:IKT) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk.
Inhibikase Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500.
PHAXIAM Therapeutics has higher revenue and earnings than Inhibikase Therapeutics.
In the previous week, Inhibikase Therapeutics' average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.
Inhibikase Therapeutics received 5 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users.
3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 20.3% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
PHAXIAM Therapeutics has a net margin of 0.00% compared to Inhibikase Therapeutics' net margin of -5,886.15%. PHAXIAM Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.
Inhibikase Therapeutics currently has a consensus target price of $27.00, indicating a potential upside of 1,709.89%. Given Inhibikase Therapeutics' higher possible upside, equities research analysts clearly believe Inhibikase Therapeutics is more favorable than PHAXIAM Therapeutics.
Summary
Inhibikase Therapeutics and PHAXIAM Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Inhibikase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inhibikase Therapeutics Competitors List
Related Companies and Tools
